Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adenocarcinoma
New adenocarcinoma findings from Technical University of Munich described
December 2nd, 2008
"Pancreatic ductal adenocarcinoma (PDAC) is a highly desmoplastic tumor with an innate resistance to therapy. Pancreatic stellate cells (PSCs) produce this excessively desmoplastic microenvironment," scientists in Munich, Germany report. "The impact of PSC activity on PDAC behavior in vivo is analyzed. 233 patients who underwent surgery for PDAC were evaluated by immunohistochemistry using antibodies against a-smooth muscle actin as a marker of PSC activity. Aniline was used to stain collagen deposition. The ratio of a-smooth muscle actin-stained area to collagen-stained area was defined as the activated stroma index (ASI). Survival analysis was performed using the...
Source: Cancer Weekly (2008-12-02)
|
